
|Videos|June 10, 2021
What To Know About Aducanumab and Slowing the Progression of Alzheimer Disease
Pharmacy Times spoke to Dr. Douglas Scharre, neurologist and director of the division of Cognitive Neurology at Ohio State Wexner Medical Center, about the latest FDA approved drug for Alzheimer disease.
Advertisement
Pharmacy Times spoke to Dr.Douglas Scharre, neurologist and director of the division of Cognitive Neurology at Ohio State Wexner Medical Center, about the latest FDA approved drug for Alzheimer disease.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Redefining the Role of GLP-1 Therapies: The Clinical Trials Behind the Expanding Indications
2
FDA Approves Sibeprenlimab for Patients with IgAN
3
Gluteus Maximus Muscle Shape Changes Tied to Aging, Frailty, and Type 2 Diabetes
4
Understanding Cyclobenzaprine Hydrochloride: An Emerging Therapy for Fibromyalgia
5

















































































































































































































